Already a Leader in Comparability of Biosimilars, New R&D Initiative Aligns BioOutsources’ Strategy with the Next Generation of Biosimilars, to Support Client Testing Requirements and Leverage Rapid Growth in Biosimilars Market GLASGOW, Scotland and CAMBRIDGE, Mass. – 3rd November 2014 – BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and biosimilar characterisation for More
Adventitious agent testing using in vivo protocols: a BioOutsource Position Paper (2014).
The approaching biosimilars tidal wave puts the question of animal testing for biologics further under scrutiny. Read our Chief Scientific Officer, Dr Daniel Galbraith’s article in GEN Exclusives. Follow this link to read the full article. For more detail on this issue, read our team’s position paper: Adventitious agent testing using in vivo protocols: A BioOutsource Position More
CSO, Dr Daniel Galbraith’s article on how biosimilars have prompted CROs to be more flexible and for developers to seek focused, niche testing partners.
GLASGOW, Scotland. – 19 June, 2014 – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organisation (CTO) today announced their partnership with PsiOxus Therapeutics Ltd. to support clinical sample analysis of their Phase I/II OCTAVE (Ovarian Cancer) study. PsiOxus Therapeutics, Ltd., an Oxford, based biotechnology company, has been awarded a £1.7 million grant towards a Phase More
A global leader in ADC characterisation, BioOutsource, partners with Glythera. Exhibits at World ADC Summit in Frankfurt. GLASGOW, Scotland. – 18 February 2014 – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organization (CTO) has amplified its position as a global leader inAntibody Drug Conjugates (ADC) characterisation and are pleased to announce a partnership with More
Already a Leader in Biosimilar Services, Company’s Biosimilars Analysis Capacity to Double with Addition of New Facility Glasgow, Scotland, February 5, 2014 , BioOutsource Ltd. (“BioOutsource”), a global leader in biologics contract testing and biosimilar characterization for the biopharmaceutical industry, today announced the opening of a new Biosimilar Centre of Excellence in Glasgow. The new More
Chief Scientific Officer, Daniel Galbraith writes on the fast growing Biosimilar market, published in Industry Voices section by FierceBiotech. Read the article here.
BioOutsource Launches Comprehensive Range of Off-the-Shelf Testing Methodologies to Support Biosimilar Characterisation & Comparability Testing
Expands Glasgow, Scotland Testing Facilities and Ramps up Commercial Activities in US and Asia-Pacific GLASGOW, Scotland – September 20, 2013 – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organization (CTO) has consolidated its position as the leading expert in the biological analysis of Biosimilar Monoclonal Antibodies for the biopharmaceutical industry. Strategic internal R&D investment More